AllSci News
Boehringer Ingelheim acquires viral vector platform from Prime Vector Technologies for cancer vaccines
Boehringer Ingelheim has entered a license agreement with Germany-based Prime Vector Technologies GmbH (PVT) to acquire exclusive rights to its Orf virus...
Merck ends Phase II Alzheimer's trial of MK-1167 after interim efficacy failure
Merck's Phase II MK-1167-008 trial evaluating MK-1167, an oral M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 PAM), in mild to...
Compass Pathways' COMP360 becomes first classic psychedelic to prove durable six-month benefit in TRD
Compass Pathways plc (Nasdaq: CMPS) has reported 26-week data from its second Phase III trial of COMP360, a synthetic psilocybin formulation for...
Kailera's oral GLP-1 agonist HRS-7535 delivers weight loss but trails injectable rivals in obesity race
Kailera Therapeutics (Nasdaq: KLRA) reported positive topline data from two Hengrui Pharma-sponsored Phase III trials of HRS-7535, an oral small molecule...
Semnur secures USD 100m from Kazakhstan investor to advance non-opioid pain candidate
Palo Alto-based Semnur Pharmaceuticals, Inc. (OTC: SMNR), a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), announced the signing of a...
EMA begins phased review of Revolution's daraxonrasib as FDA filing nears completion
Revolution Medicines (Nasdaq: RVMD) has initiated a rolling submission of a New Drug Application (NDA) to the US FDA for daraxonrasib (RMC-6236), an...
Insilico's AI-designed TNIK inhibitor rentosertib advances to Phase III IPF trial
Insilico Medicine (HKEX: 3696) has initiated a Phase III clinical trial for rentosertib (formerly ISM001-055 / INS018055), its first-in-class oral TNIK...
Teva reports early vitiligo data for anti-IL-15 TEV-'408, advances into Phase IIb
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) reported Phase Ib data for TEV-'408, its internally discovered anti-IL-15 monoclonal antibody, and...
HMNC reports peer-reviewed oral ketamine data showing reduced dissociation in treatment-resistant depression
Germany-based HMNC Brain Health (HMNC Holding GmbH) reported peer-reviewed results from the Ketabon KET01 clinical trial program in JAMA Network Open on...
Saol Therapeutics resubmits rare mitochondrial disease drug after FDA agreement
Roswell, Georgia-based Saol Therapeutics has resubmitted its New Drug Application (NDA) to the US FDA for SL1009 (sodium dichloroacetate, or DCA), seeking...
MeiraGTx secures USD 400m from Oberland Capital to fund gene therapy commercialization
UK-based MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment of up to USD 400 million from Oberland Capital Management LLC, structured to...
Organogenesis advances first amniotic tissue biologic to FDA review for knee osteoarthritis
The US FDA's acceptance of a Biologics License Application (BLA) for Amnuvx (azimplacel, formerly Renu) — a cryopreserved amniotic suspension allograft for...
Kalohexis files confidential IPO as oral non-GLP-1 obesity biotech enters public markets
Northbrook, Illinois-based Kalohexis, Inc. — a clinical-stage biotechnology company targeting the melanocortin receptor system for obesity and cancer...
FDA grants priority review to Agios’ mitapivat as first oral PK activator for sickle cell disease
Agios Pharmaceuticals (Nasdaq: AGIO) announced that the US FDA has granted Priority Review to its supplemental New Drug Application (sNDA) for mitapivat…
Abivax secures USD 920m to fund US launch of inflammatory bowel disease candidate
France-based Abivax SA (Euronext Paris / Nasdaq: ABVX) announced the closing of a USD 920 million (EUR 807 million) Abivax public offering of American...
The AllSci Brief
Systematic R&D and deal news. Daily.